March 2, 2021

J&J Moves Ahead with Vaccination, But Still Testing a Two-Dose Approach

J&J Moves Ahead with Vaccination, But Still Testing a Two-Dose Approach

Another vaccine has been added to the list of shots given the green-light by the FDA in the fight against Covid-19.

The one-and-done vaccine by Johnson and Johnson uses an adenovirus vector, which makes it the first non-mRNA shot to be distributed state-side; but also the first one that does not require a follow-up dose.

We know that organizations like the World Health Organization have put forward their recommendation that a single shot during a pandemic period has a lot of advantages with regard to being able to vaccinate with more ease,” Rick Nettles, Vice President of Medical Affairs for Janssen explained in this week’s episode. “You can really simplify the logistics if you have a one-shot approach.”

An approach, he says, that allows the vaccine to target certain populations where returning for a second shot will be more difficult.

“Think about populations that have issues with travel or that have issues with finding themselves available for the second shot; transient populations, homeless populations. And then again in rural populations where people have to travel long distances to get that second shot, this opens up the possibility of vaccinating people like that,” he explained.

He also addresses:

  • How the J&J shot is different than the others
  • Why they went with an Adenovirus vector and  how it  will protect against different strains.
  • What to expect when you get the vaccine-- sore arms? Fevers?
  • When we can expect to see a shot for kids, pregnant  women, and  immunocompromised
  •  Why they are also studying a two-dose approach


Listen along with us on: Apple Podcasts,Spotify, or wherever you listen